Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Autoimmune Disorders01:29

Autoimmune Disorders

792
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
792
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

35
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
35
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

72
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
72
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

744
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
744
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

5.6K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
5.6K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

109
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
109

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the feasibility of modeling next-day fatigue and sleepiness using digital sleep tracker data in neurodegenerative and immune-mediated inflammatory diseases.

Frontiers in digital health·2026
Same author

Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study.

The Lancet. Rheumatology·2026
Same author

Can real-world measures of activity, sleep, and cardiorespiratory function stratify Sjogren's disease participants with persistent fatigue? Insights from the BRC tools study.

EULAR rheumatology open·2026
Same author

Technology Acceptance of 2 mHealth Apps During an Observational Technology Evaluation Study: Qualitative Results of a Mixed Methods Study.

JMIR human factors·2026
Same author

IDEA-FAST clinical study protocol: Identifying digital end-points of fatigue, sleep quality and daytime sleepiness in N = 2000.

Digital health·2026
Same author

The SjD Map: an interactive pathway tour into Sjögren's disease signalling mechanisms.

NPJ systems biology and applications·2026

Related Experiment Video

Updated: Oct 8, 2025

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

3.4K

New developments in Sjogren's syndrome.

Nishanthi Thalayasingam1, Kelly Baldwin1, Claire Judd1

  • 1Department of Rheumatology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust.

Rheumatology (Oxford, England)
|December 24, 2021
PubMed
Summary
This summary is machine-generated.

Sjogren's syndrome (SS) treatments offer only symptomatic relief. New strategies targeting B-cells show promise for altering disease progression, necessitating refined clinical trials for effective therapies.

Keywords:
B-cellsBAFFCD40SSbiologicsoutcome measuresstratification

More Related Videos

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

1.3K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

566

Related Experiment Videos

Last Updated: Oct 8, 2025

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research
07:25

Author Spotlight: A Focus on Standardized Salivary Gland Ultrasound Protocol in Connective Tissue Disease Research

Published on: October 13, 2023

3.4K
Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

1.3K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

566

Area of Science:

  • Immunology
  • Rheumatology
  • Autoimmune Diseases

Background:

  • Sjogren's syndrome (SS) is a chronic autoimmune disorder affecting exocrine glands via lymphocytic infiltration and B-cell dysfunction.
  • Current treatments provide only symptomatic relief, lacking efficacy in altering disease progression or systemic manifestations.
  • B-cell depletion therapy's clinical effectiveness in systemic SS remains unproven in large randomized controlled trials.

Purpose of the Study:

  • To review the current landscape of Sjogren's syndrome treatment.
  • To highlight emerging therapeutic strategies targeting B-cells.
  • To emphasize the need for improved clinical trial design in SS.

Main Methods:

  • Review of current literature on Sjogren's syndrome pathogenesis and treatment.
  • Analysis of clinical trial data regarding B-cell targeted therapies.
  • Discussion of future directions for SS research and clinical trials.

Main Results:

  • Existing SS therapies are empirical and do not modify disease course.
  • B-cell depletion has shown limited proven efficacy in randomized trials.
  • Alternative B-cell targeting strategies, such as co-stimulation blockade, show promising preliminary data.

Conclusions:

  • Novel therapeutic approaches focusing on B-cell modulation are under investigation for Sjogren's syndrome.
  • Successful clinical trials in SS require patient stratification and sensitive outcome measures.
  • Future research should focus on developing treatments that address the underlying autoimmune processes in SS.